Evolutionary variation of the monkeypox virus detected for the first time in Nantong, Jiangsu DOI Creative Commons

Xingpei Ji,

Ruyue Liang,

Chao Bao

и другие.

Virology Journal, Год журнала: 2024, Номер 21(1)

Опубликована: Дек. 23, 2024

Monkeypox (MPOX) is a zoonotic disease caused by Orthopoxvirus monkeypox (MPXV), belonging to the genus, and exhibits symptoms similar smallpox. In 2024, outbreak in Democratic Republic of Congo continued develop, raising widespread global public health concerns. September 2023, first local was reported Nantong, Jiangsu Province, China. Whole-genome sequencing samples from seven confirmed patients identified new lineage, C.1.1, which may be related imported cases Japan. Evolutionary analysis MPXV showed fewer mutations mediated Apolipoprotein B mRNA Editing Catalytic polypeptide-like 3 (APOBEC3). Additionally, N2L protein disrupted transcription initiation, while changes Cytomegalovirus-encoded immunomodulatory (CrmB) led structural instability protein. It hoped that these findings will provide insights for future research on evolutionary mechanisms virus development vaccines.

Язык: Английский

Unveiling the Global Surge of Mpox (Monkeypox): A comprehensive review of current evidence DOI Creative Commons
Phelipe Magalhães Duarte, Ridwan Olamilekan Adesola, Swagatika Priyadarsini

и другие.

The Microbe, Год журнала: 2024, Номер 4, С. 100141 - 100141

Опубликована: Авг. 17, 2024

Monkeypox, now named mpox, has emerged as a significant public threat, evidenced by the 2022 outbreak affecting over seventy countries globally. This infectious disease presents debilitating symptoms, including painful skin rashes, mucosal lesions, enlarged lymph nodes, and fever. The situation intensifies with concerns about novel transmission route, specifically through sexual contact, evolution of more transmissible strains. Complicating matters further is documented spillback mpox from humans to animals, raising potential for new animal reservoirs. study utilized systematic approach gather, analyse, interpret data regarding global outbreaks, phylogenomics, human APOBEC3 enzyme activity, antiviral resistance issues, application One Health intervention. Emphasizing covers various aspects, zoonotic origins, pathogenesis, changing epidemiological landscapes, phylogenomic diversity, clade dynamics. review underscores crucial role collaboration in understanding combatting making it valuable resource shaping effective prevention control measures on scale.

Язык: Английский

Процитировано

21
Mpox 2024: New variant, new challenges, and the looming pandemic DOI Creative Commons
Amogh Verma, Mahalaqua Nazli Khatib, Gopal Ashish Sharma

и другие.

Clinical Infection in Practice, Год журнала: 2024, Номер unknown, С. 100394 - 100394

Опубликована: Окт. 1, 2024

Язык: Английский

Процитировано

9
Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein DOI Creative Commons
Shimeng Bai,

Yanxin Cui,

Qibin Liao

и другие.

Viruses, Год журнала: 2025, Номер 17(1), С. 116 - 116

Опубликована: Янв. 16, 2025

The re-emergence of the mpox pandemic poses considerable challenges to human health and societal development. There is an urgent need for effective prevention treatment strategies against virus (MPXV). In this study, we focused on A35R protein created a chimeric A35R-Fc by fusing Fc region IgG its C-terminal. We then assessed reactivity with A35R-specific antibodies convalescent plasma, as well immunogenicity. Our findings indicate that significantly enhances affinity compared commercially available exhibits plasma. Additionally, mice immunized exhibited increased neutralizing antibody titers live MPXV. These results support potential domain antigens strategy enhance efficacy subunit vaccines targeting

Язык: Английский

Процитировано

1
Mpox Virus as a Global Public Health Emergency: A Scoping Review DOI Creative Commons
Sathish Sankar, Pachamuthu Balakrishnan, Yean K. Yong

и другие.

Canadian Journal of Infectious Diseases and Medical Microbiology, Год журнала: 2025, Номер 2025(1)

Опубликована: Янв. 1, 2025

The monkeypox (Mpox) virus has emerged as a global public health emergency of international concern recently. that was endemic in West and Central Africa now been reported with chains transmission to several countries. A scoping review carried out from the relevant literature available PubMed, Scopus Web Science. This comprehensive analysis describes epidemiology, pathogenesis, clinical manifestations, complications including secondary bacterial infections, diagnosis, treatment vaccination. article underscores significance key viral immune mediators infection discusses updated recommendations on therapeutic strategies

Язык: Английский

Процитировано

1
Plant-derived molecules in monkeypox management: insight and alternative therapeutic strategies DOI Creative Commons
Martin Ndayambaje, Emmanuel Munyeshyaka,

Olive Dieumerci

и другие.

Beni-Suef University Journal of Basic and Applied Sciences, Год журнала: 2025, Номер 14(1)

Опубликована: Фев. 19, 2025

Abstract The WHO and CDC recently declared monkeypox virus (MPXV) a zoonotic disease known as (Mpox) Public Health Emergency of International Concern. According to the CDC, no treatment is specifically approved for Mpox infections. Medicinal plants are crucial in healthcare economic development, particularly low- middle-income countries. This review offers valuable insights into pathogenesis management through therapeutic approaches vaccination strategies using plant-based molecules. Core structural proteins necessary both viral entry immune response, including A29, H3L, L1R, involved MPXV. Potential targets vaccines include like A35R B6R, which essential propagation viruses. MPXV evades system by concealing its DNA, suppressing interferon limiting T NK cell activation, preventing apoptosis, complicating vaccine development. Antivirals (tecovirimat, brincidofovir) vaccinations (JYNNEOS, ACAM2000) manage Mpox. A recent study revealed early clinical trial results, indicating that antiviral drug tecovirimat, well-known conventional treatment, more effective than placebo against clade I type Research gaps, low effectiveness, availability challenges. novel perspective on combating global threat investigating alternative centered plant-derived compounds. Graphical

Язык: Английский

Процитировано

1
Interdisciplinary Approach to Monkeypox Prevention: Integrating Nanobiosensors, Nanovaccines, Artificial Intelligence, Visual Arts, and Social Sciences DOI Creative Commons
Vishal Chaudhary,

Lucky Lucky,

Harsh Sable

и другие.

Small Structures, Год журнала: 2025, Номер unknown

Опубликована: Фев. 19, 2025

To effectively address crisis emergence of new virus such as monkeypox, a collective and collaborative effort between scientists, engineers, innovators, artists from all ages, regions, diverse fields is required. This review explores holistic approach to addressing the monkeypox by integrating nanobiosensors, artificial intelligence, visual arts, humanities, social sciences. Traditional diagnostic methods are often limited time, accessibility, accuracy, but advancement point‐of‐care smart nanobiosensors offers promising shift toward rapid, precise, accessible diagnostics. They enhance ability screen, diagnose, monitor infections efficiently, contributing better disease management. Beyond technological innovation, essential role sciences in fostering public engagement, understanding, acceptance tools emphasized. Visual arts can illustrate scientific concepts, making them more relatable, while storytelling through various media reduce stigma promote preventive measures. Social provide insights into cultural attitudes, behaviors, health challenges, ensuring that solutions integrated communities. By combining these disciplines, this presents comprehensive framework for resilient global system aligns with One Health principles, emphasizing interconnectedness human, animal, environmental health.

Язык: Английский

Процитировано

1
Advances and challenges of monkeypox detection technology DOI Creative Commons
Wenjing Liu,

Erxin Zhang,

Wei Li

и другие.

Biosafety and Health, Год журнала: 2024, Номер 6(5), С. 260 - 269

Опубликована: Сен. 11, 2024

Язык: Английский

Процитировано

5
Structure-based drug designing for potential antiviral activity of selected natural product against Monkeypox (Mpox) virus and its host targets DOI

Vimal K. Maurya,

Swatantra Kumar,

Shivani Maurya

и другие.

VirusDisease, Год журнала: 2024, Номер 35(4), С. 589 - 608

Опубликована: Ноя. 29, 2024

Язык: Английский

Процитировано

3
Monkeypox virus H3L protein as the target antigen for developing neutralizing antibody and serological assay DOI Creative Commons
I‐Hsiang Huang,

Guan-Chun Lai,

Tai‐Ling Chao

и другие.

Applied Microbiology and Biotechnology, Год журнала: 2025, Номер 109(1)

Опубликована: Апрель 2, 2025

The large number of atypical monkeypox (Mpox) cases caused by emerging virus (MPXV) strains was recently found in countries and regions where the Mpox not reported before. Diagnostic tools therapeutic agents are important countermeasures for preventing outbreak. H3L protein is surface antigen MPXV binding to host cell receptors mediating viral infection. A broad range murine anti-MPXV monoclonal antibodies (mAbs) recognizing various epitopes have been generated study. rapid test composed mAbs 4-2A 3-3F can specifically detect virion. mAb exhibited strong neutralizing activity a complement-dependent manner. Notably, binds unique epitope within residues 35-89 protein. serum samples collected from patients barely bound N-terminal portion ranging 2 89 residues, indicating that content 3-3F-like antibody very low patient sera. In contrast, seropositivity mostly observed using C-terminal 185 282 as target immunoblot analysis. Taken together, be developed diagnostic agents. Furthermore, promising biomarker serological KEY POINTS: •Anti-H3L cross-react with proteins VACV virions. •The LFIA MPXV. •MPXV neutralized

Язык: Английский

Процитировано

0
Current status of next-generation vaccines against mpox virus: a scoping review DOI Creative Commons
Luis Alberto Bravo-Vázquez,

Daniela Bernal-Vázquez,

Asim K. Duttaroy

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 28, 2025

The mpox disease, caused by the virus (MPXV), has become a rising public health issue due to its potential cause outbreaks. Consistently, this investigation aims evaluate current advances in development of novel immunotherapeutic approaches against MPXV, which are crucial for preventing and controlling spread. This scoping review was performed analyzing content English-language articles published between 2018 2024, reported next-generation vaccines MPXV their assessment animal models. Patents within scope research were also included. Contrarywise, studies based solely on immunoinformatic methods, reviews, book chapters, news, others excluded. literature search executed 11 databases, such as Scopus, MEDLINE, PubMed. A total 36 records (32 4 patents) included review. All 32 contain preclinical with varied group sizes (4-16) main models BALB/c mice. Less commonly used CAST/Ei mice cynomolgus macaques. Moreover, most targeted one or more antigens, A29L, A35R, B6R, M1R, through active immunization (via mRNAs recombinant antigens) passive (antibody delivery). Overall, new generation might represent prospective candidates combat concern. Nonetheless, several analyzed possess drawbacks, including limited similarity humans, small sizes, brief follow-up durations. Consequently, additional is required ascertain long-term protection, efficacy, safety these approaches.

Язык: Английский

Процитировано

0